TISSIUM, a privately-owned life science company developing fully synthetic, biomorphic programmable polymers, announced today it has raised €38.75million ($42.78 million)in a Series B roundof funding.

This funding round comprisesnew investors BNP Paribas Développement, the European Investment Fund (EIF), M&L Investments, ValQuest Partnersin addition to TISSIUM’s returning investors Bpifrance, CM-CIC Innovation, Cap Decisif Management, Omnes Capital and Sofinnova Partners.